


Opioids and Other Analgesics Are The Fastest-Growing Neurology Drugs

LONDON, GREATER LONDON, UK, June 21, 2018 /EINPresswire.com/ -- The global market for analgesics, which includes opioids as well as anti-inflammatory drugs to relieve localized pain, is growing at over 8% year on year, [a report from The Business Research Company shows](#). This compares with 6% for anaesthetics and 5% for anti-Parkinson drugs. Analgesics are drugs that relieve pain selectively without blocking the conduction of nerve impulses, noticeably changing sensory perception, or affecting consciousness. There are two types of analgesics – anti-inflammatory drugs that relieve modest pain by reducing local inflammatory responses and the opioids that act on the brain to reduce chronic pain.



In some parts of the world, such as the USA, experts suggest, there is an opioid crisis, resulting from the addictive properties of these drugs. It is claimed that more than two million Americans have become dependent on or abused prescription pain pills and street drugs. The number of opioid prescriptions dispensed by US doctors steadily increased from 112 million prescriptions in 1992 to a peak of 282 million in 2012, according to the market research firm IMS Health. Although the number of prescriptions dispensed has since declined, falling to 236 million in 2016, in that year there were still more than 42,249 overdose deaths that involved an opioid and Americans were the consumers of around 99% of all synthetic opioid drugs.

Analgesics are a segment of the wider market for drugs to treat neurological diseases, where growth is concentrated in smaller markets, particularly the BRICs (Brazil, Russia, India and China). The market for these drugs to treat diseases of the central nervous system (brain, spinal cord and nerves) in the four BRICs will all grow at 10% a year or above up to 2021. In the case of China and India this follows on from growth at this high level since 2010. Despite their large populations, however, the BRICs account for only a small proportion of the world's market for these drugs - 10% in 2017. In these emerging markets greater affordability of treatment resulting from growing GDP per capita and to some degree the arrival of low-priced generics help account for growth in the markets for these drugs.

In contrast with the rapid growth in the BRICs, the overall neurological drugs market in the USA, easily the world's largest, has been sluggish at 4%, though growing at a slightly faster 6% going forward. The Western European countries and Japan also have only moderate growth in the markets for these central nervous system drugs, so helping to hold back global growth to 5%. The global market will be worth \$87 billion in 2021, around 7.4% of the total for all pharma.

Drugs for neurological diseases are used to treat disorders such as epilepsy, Alzheimer's disease and other dementias, cerebrovascular diseases including stroke, migraine and other headache disorders,

multiple sclerosis, Parkinson's disease, neuroinfections, traumatic disorders of the nervous system due to head trauma, and neurological disorders as a result of malnutrition.

The market for analgesic drugs is relatively concentrated, with the ten largest companies taking nearly 60% of the total. Biogen Inc. is market leader, followed by Johnson & Johnson, Pfizer, F. Hoffmann-La Roche and Novartis. Biogen's Multiple Sclerosis Division, which manufactures central nervous system drugs, generated revenues of \$8.3 billion for the financial year 2016, a 1.1% decrease from the previous year. Johnson & Johnson's Total Neuroscience Division, that manufactures central nervous system drugs, also saw its revenues decrease, this time by 2.8% from the previous year. Smaller branded pharma rivals and generic drug manufacturers, however, benefitted from growing revenues from CNS drugs in 2016.

Where To Learn More

Read the [Pharmaceutical Drugs Global Market Report 2018](#) from [The Business Research Company](#) for information on the following:

Markets Covered: Musculoskeletal disorder drugs, cardiovascular drugs, oncology drugs, anti-infective drugs, metabolic disorder drugs, central nervous system drugs, genito-urinary drugs, gastrointestinal drugs, hematology drugs, dermatology drugs, ophthalmology drugs, drugs for respiratory diseases.

Pharmaceutical Companies Covered: Novartis AG, Sanofi S.A., F. Hoffman-La Roche Ltd., Pfizer Inc. and Gilead Sciences Inc.

Regions: North America, Asia Pacific, Western Europe, South America, Eastern Europe, Middle East, Africa.

Countries: USA, China, Japan, Germany, Brazil, France, Italy, UK, Australia, India, Spain, Russia.

Time Series: Five years historic (2013-17) and forecast (2017-21).

Data: Ratios of market size and growth to related markets, population, GDP, Pharmaceutical Drugs Indicators Comparison.

Data Segmentations: Pharmaceutical drugs global market, global pharmaceutical drugs market by therapeutic area segments and sub segments; pharmaceutical drugs market by region and country and by therapeutic area segments; branded versus generic drugs markets by country; competitor drug sales and market shares by therapeutic area; global healthcare market historic and forecast size and growth; healthcare market regional and country size and growth; healthcare market competitive landscape.

Other Information: PESTEL analysis, drivers and restraints, customer information, pharmaceutical drugs market by region and country covering new drugs trials and approvals, regulations, government initiatives and competitive landscape; pharmaceutical drugs market trends and strategies.

Sourcing and Referencing: Data and analysis throughout the report are sourced using end notes. Sources include primary as well as extensive secondary research.

Interested to know more? Here is a list of reports similar to "Pharmaceutical Drugs Global Market Report 2018":

1. Central Nervous System Drugs Global Market Report 2018
2. Biologics Global Market Report 2018
3. Contract Research Organizations Global Market Report 2018
4. Organ-on-Chip Global Market Report 2018

Oliver Guirdham

The Business Research Company

+44 207 1930 708

email us here

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.
© 1995-2018 IPD Group, Inc. All Right Reserved.